Minoru Fujimoto

List of Publications by Year
in descending order

96 papers	5,789 citations	76294 40 h-index	79644 73 g-index
97 all docs	97 docs citations	97 times ranked	7881 citing authors

#	Article	IF	Citations
1	Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2022, 51, 126-133.	1.4	5
2	LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway. Biochemical and Biophysical Research Communications, 2021, 537, 93-99.	1.0	6
3	The involvement of leucine-rich Î±-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Modern Rheumatology, 2021, 31, 1120-1128.	0.9	8
4	The Skinâ€“Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich Î±-2 Glycoprotein. Journal of Immunology, 2021, 206, 1469-1477.	0.4	6
5	Leucineâ€rich Î±â€2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis. Journal of Cutaneous Immunology and Allergy, 2021, 4, 86-88.	0.2	0
6	Anti-Glypican-1 Antibodyâ€“drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1â€“Positive Cholangiocarcinoma. Molecular Cancer Therapeutics, 2021, 20, 1713-1722.	1.9	10
7	A glypican-1-targeted antibody-drug conjugate exhibits potent tumorÂgrowth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia, 2021, 23, 939-950.	2.3	9
8	Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibodyâ€“Drug Conjugates in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 2495-2505.	1.9	14
9	Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. British Journal of Cancer, 2021, 125, 1511-1522.	2.9	16
10	TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naÃ¯ve and imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 2020, 122, 658-667.	2.9	37
11	Correlation of increased serum leucine-rich Î±2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study. PLoS ONE, 2020, 15, e0234090.	1.1	7
12	Anti-glypican-1 antibodyâ€“drug conjugate is a potential therapy against pancreatic cancer. British Journal of Cancer, 2020, 122, 1333-1341.	2.9	27
13	Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis. Scientific Reports, 2020, 10, 3384.	1.6	15
14	Evaluation of leucine-rich alpha-2 glycoprotein as a biomarker of fetal infection. PLoS ONE, 2020, 15, e0242076.	1.1	7
15	Epithelialâ€mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein <scp>leucineâ€rich alphaâ€2 glycoprotein</scp>. Cancer Science, 2019, 110, 985-996.	1.7	20
16	SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3ÂK signaling. Gastric Cancer, 2018, 21, 968-976.	2.7	9
17	Leucine rich Î±-2 glycoprotein is a potential urinary biomarker for renal tubular injury. Biochemical and Biophysical Research Communications, 2018, 498, 1045-1051.	1.0	29
18	Antiâ€glypicanâ€1 antibodyâ€drug conjugate exhibits potent preclinical antitumor activity against glypicanâ€1 positive uterine cervical cancer. International Journal of Cancer, 2018, 142, 1056-1066.	2.3	52

#	Article	IF	Citations
19	LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake. Cancer Research, 2018, 78, 516-527.	0.4	31
20	LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunological Medicine, 2018, 41, 62-67.	1.4	43
21	NQO1 inhibits the TLR-dependent production of selective cytokines by promoting Iº B-Î¶ degradation. Journal of Experimental Medicine, 2018, 215, 2197-2209.	4.2	37
22	Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cellâ€“Mediated Antitumor Immunity By Suppressing PD-L1. Molecular Cancer Therapeutics, 2018, 17, 1941-1950.	1.9	10
23	Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. Oncotarget, 2018, 9, 32917-32928.	0.8	16
24	Leucine-rich Î±-2 glycoprotein is an innovative biomarker for psoriasis. Journal of Dermatological Science, 2017, 86, 170-174.	1.0	24
25	Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. International Journal of Cancer, 2017, 140, 2608-2621.	2.3	31
26	Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-Î²-Smad2 signaling in naÃ¯ve helper T cells. Arthritis Research and Therapy, 2017, 19, 137.	1.6	45
27	SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma. Cancer Research, 2017, 77, 6975-6986.	0.4	39
28	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 84-91.	0.6	100
29	Leucine-rich Î± -2 glycoprotein promotes lung fibrosis by modulating TGF-Î² signaling in fibroblasts. Physiological Reports, 2017, 5, e13556.	0.7	38
30	Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 24741-24752.	0.8	46
31	Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. Cardiovascular Research, 2016, 109, 272-282.	1.8	36
32	Cell surface localization of importin Î±1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling. Scientific Reports, 2016, 6, 21410.	1.6	33
33	Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. British Journal of Cancer, 2016, 115, 66-75.	2.9	76
34	Increased serum CXCR2 ligand levels in livedo vasculopathy with winter ulcerations: Possible contribution of neutrophil recruitment to lesional skin. Journal of Dermatological Science, 2016, 82, 57-59.	1.0	3
35	Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. British Journal of Cancer, 2016, 114, 554-561.	2.9	22
36	Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation. PLoS ONE, 2016, 11, e0153399.	1.1	15

#	Article	IF	Citations
37	Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma. PLoS ONE, 2016, 11, e0162672.	1.1	44
38	Saltâ€inducible kinase 3 deficiency exacerbates lipopolysaccharideâ€induced endotoxin shock accompanied by increased levels of proâ€inflammatory molecules in mice. Immunology, 2015, 145, 268-278.	2.0	28
39	CpG oligodeoxynucleotides potentiate the antitumor activity of antiâ€<scp>BST</scp>2 antibody. Cancer Science, 2015, 106, 1474-1478.	1.7	11
40	Suppressor of cytokine signallingâ€1 induces significant preclinical antitumor effect in malignant melanoma cells. Experimental Dermatology, 2015, 24, 864-871.	1.4	14
41	Leucine-rich Î±-2-glycoprotein promotes TGFÎ²1-mediated growth suppression in the Lewis lung carcinoma cell lines. Oncotarget, 2015, 6, 11009-11022.	0.8	31
42	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaudâ€™s phenomenon. Rheumatology, 2015, 54, 349-358.	0.9	14
43	Brief Report: Leucineâ€Rich Î±₂â€Glycoprotein as a Potential Biomarker for Joint Inflammation During Antiâ€“Interleukinâ€6 Biologic Therapy in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2056-2060.	2.9	71
44	Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis. British Journal of Cancer, 2015, 113, 433-442.	2.9	21
45	CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6. Experimental Eye Research, 2015, 140, 53-64.	1.2	7
46	Histamine Contributes to Tissue Remodeling via Periostin Expression. Journal of Investigative Dermatology, 2014, 134, 2105-2113.	0.3	34
47	Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. International Journal of Cancer, 2014, 134, 1796-1809.	2.3	28
48	Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment. Pigment Cell and Melanoma Research, 2014, 27, 630-639.	1.5	50
49	Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Oncotarget, 2014, 5, 7776-7787.	0.8	24
50	SOCSâ€1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. International Journal of Cancer, 2013, 132, 459-471.	2.3	25
51	Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. International Journal of Cancer, 2013, 132, 472-484.	2.3	56
52	New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. International Journal of Cancer, 2013, 133, n/a-n/a.	2.3	35
53	Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signalingâ€1 in nonâ€smallâ€cell lung cancer cells. Cancer Science, 2013, 104, 1483-1491.	1.7	28
54	Dysregulation of melanocyte function by Th17â€related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell and Melanoma Research, 2012, 25, 219-230.	1.5	123

#	Article	IF	Citations
55	Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma. American Journal of Pathology, 2012, 180, 165-176.	1.9	115
56	Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflammatory Bowel Diseases, 2012, 18, 2169-2179.	0.9	161
57	Antiproliferative effect of SOCSâ€1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. International Journal of Cancer, 2012, 131, 1287-1296.	2.3	57
58	Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. Experimental Dermatology, 2012, 21, 331-336.	1.4	101
59	Periostin Facilitates Skin Sclerosis via PI3K/Akt Dependent Mechanism in a Mouse Model of Scleroderma. PLoS ONE, 2012, 7, e41994.	1.1	89
60	The Influence of Excessive IL-6 Production In Vivo on the Development and Function of Foxp3+ Regulatory T Cells. Journal of Immunology, 2011, 186, 32-40.	0.4	133
61	Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. Journal of Controlled Release, 2011, 149, 58-64.	4.8	22
62	Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis. Inflammatory Bowel Diseases, 2011, 17, 491-502.	0.9	19
63	Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. International Journal of Cancer, 2011, 129, 993-1005.	2.3	42
64	Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Proteinâ€“Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis. , 2011, 52, 3264.		70
65	IL-6-mediated Th17 differentiation through RORÎ³t is essential for the initiation of experimental autoimmune myocarditis. Cardiovascular Research, 2011, 91, 640-648.	1.8	72
66	Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociationâ˜†. Journal of Controlled Release, 2010, 143, 311-317.	4.8	131
67	SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterology Research and Practice, 2010, 2010, 1-7.	0.7	95
68	Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. International Immunology, 2010, 22, 359-366.	1.8	14
69	iTRAQ-based proteomic identification of leucine-rich Â-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Annals of the Rheumatic Diseases, 2010, 69, 770-774.	0.5	179
70	Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Experimental Eye Research, 2010, 91, 162-170.	1.2	82
71	Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. International Journal of Cancer, 2009, 125, 2316-2322.	2.3	59
72	Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors. Proteomics - Clinical Applications, 2008, 2, 1246-1254.	0.8	5

#	Article	IF	Citations
73	Interleukinâ€6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis and Rheumatism, 2008, 58, 3710-3719.	6.7	211
74	Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin. Lung Cancer, 2008, 62, 45-54.	0.9	46
75	Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. International Immunology, 2008, 20, 753-762.	1.8	76
76	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9041-9046.	3.3	308
77	Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis. Proteomics - Clinical Applications, 2007, 1, 185-191.	0.8	10
78	Proteomics-based identification of ?-enolase as a tumor antigen in non-small lung cancer. Cancer Science, 2007, 98, 1234-1240.	1.7	102
79	Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochemical and Biophysical Research Communications, 2006, 340, 1-7.	1.0	72
80	IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochemical and Biophysical Research Communications, 2006, 342, 1413-1416.	1.0	92
81	Osteoblast differentiation is impaired in SOCS-1-deficient mice. Journal of Bone and Mineral Metabolism, 2006, 24, 283-290.	1.3	12
82	SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. Journal of Cellular Physiology, 2006, 207, 428-436.	2.0	22
83	Luteolin, a Flavonoid, Inhibits CD40 Ligand Expression by Activated Human Basophils. International Archives of Allergy and Immunology, 2006, 140, 150-156.	0.9	30
84	Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction. Biochemical and Biophysical Research Communications, 2005, 328, 953-961.	1.0	18
85	Negative Regulation of Cytokine and TLR Signalings by SOCS and Others. Advances in Immunology, 2005, 87, 61-122.	1.1	87
86	Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. International Immunology, 2004, 16, 303-314.	1.8	64
87	Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. British Journal of Haematology, 2004, 126, 726-735.	1.2	68
88	Flavonoids such as Luteolin, Fisetin and Apigenin Are Inhibitors of Interleukin-4 and Interleukin-13 Production by ActivatedHuman Basophils. International Archives of Allergy and Immunology, 2004, 134, 135-140.	0.9	118
89	Regulation of cytokine signaling by SOCS family molecules. Trends in Immunology, 2003, 24, 659-666.	2.9	202
90	A regulatory role for suppressor of cytokine signaling-1 in Th polarization in vivo. International Immunology, 2002, 14, 1343-1350.	1.8	66

#	Article	IF	Citations
91	SOCS-1 Participates in Negative Regulation of LPS Responses. Immunity, 2002, 17, 677-687.	6.6	583
92	SOCS-1/SSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN-Î³ and IL-4 Signaling In Vivo. Immunity, 2001, 14, 535-545.	6.6	176
93	Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation. Journal of Experimental Medicine, 2001, 193, 263-270.	4.2	138
94	Defective Thymocyte Development and Perturbed Homeostasis of T cells in STAT-Induced STAT Inhibitor-1/Suppressors of Cytokine Signaling-1 Transgenic Mice. Journal of Immunology, 2000, 165, 1799-1806.	0.4	73
95	IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN-Î³. Journal of Immunology, 2000, 164, 5833-5843.	0.4	83
96	Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends in Biochemical Sciences, 1999, 24, 394-398.	3.7	111